Accesswire
19 Jun 2026, 23:00 UTC · 11w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
Onco-Innovations intends to raise approximately CAD$5 million through a non-brokered private placement of 6,764,069 units at CAD$0.7392 per unit. — Private placements typically cause immediate share price dilution for existing shareholders.
-0.40Net proceeds will be used to advance the ONC010 program clinical development, manufacturing, preclinical testing, and the SynoGraph platform. — Dedicated funding for clinical development and platform advancement is a positive catalyst for long-term pipeline value.
+0.30The offering includes warrants allowing holders to purchase shares at CAD$0.90 for three years, with a company-led acceleration option if the 10-day VWAP reaches CAD$1.30. — Warrants create potential future dilution and can act as a ceiling on price appreciation due to the acceleration clause.
-0.20Continue reading
5 related stories
Search tags
The units will be issued under the Listed Issuer Financing Exemption, meaning they will not be subject to a hold period under Canadian securities laws. — The lack of a hold period allows immediate selling by participants, increasing short-term volatility and selling pressure.
-0.20Which stocks this story touches
The company is raising CAD$5 million in capital to advance its clinical development and technology platforms.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
13h ago
